| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CBAY | Common Stock | Options Exercise | $14,700 | +5,000 | $2.94 | 5,000 | 16 Jan 2024 | Direct | ||
| transaction | CBAY | Common Stock | Sale | $117,898 | -5,000 | -100% | $23.58 | 0 | 16 Jan 2024 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CBAY | Employee Stock Option (right to buy) | Options Exercise | $0 | -5,000 | -4.5% | $0.000000 | 107,000 | 16 Jan 2024 | Common Stock | 5,000 | $2.94 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.48 to $23.70, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022. |